Search results
Showing 1561 to 1575 of 2548 results for methods
Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids (MIB255)
NICE has developed a medtech innovation briefing (MIB) on the Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids .
NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
Axumin for functional imaging of prostate cancer recurrence (MIB172)
NICE has developed a medtech innovation briefing (MIB) on Axumin for functional imaging of prostate cancer recurrence .
NICE has developed a medtech innovation briefing (MIB) on MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery .
Stretta System for gastro-oesophageal reflux disease (MIB74)
NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
interval. This work should use qualitative as well as quantitative research methods to assess which factors influence the...